Sanofi (SANP.XC)
| Previous close | 90.82 |
| Open | 90.96 |
| Bid | 91.99 x N/A |
| Ask | 92.62 x N/A |
| Day's range | 90.82 - 90.82 |
| 52-week range | 80.89 - 104.24 |
| Volume | |
| Avg. volume | 1,155 |
| Market cap | 113.768B |
| Beta (5Y monthly) | 0.41 |
| PE ratio (TTM) | 25.16 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.76 (4.14%) |
| Ex-dividend date | 13 May 2024 |
| 1y target est | N/A |
- GlobeNewswire
Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landmark phase 3 studies showing Dupixent significantly reduced exacerbations, improved lung function and also improved health-related quality of lifeDupixent is the first new treatment approach for COPD in more than a decade and a new option for approximately 220,000 adults in the EU Approval repres
- GlobeNewswire
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
Majority of patients in this age group with eosinophilic esophagitis (EoE) receiving Dupixent achieved histologic remission, with improvements sustained up to one year Dupixent is the first and only treatment indicated for EoE in the U.S. for this age group TARRYTOWN, N.Y. and PARIS, June 26, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the New England Journal of Medicine (NEJM) has published results from a positive Phase 3 trial for Dupixent
- GlobeNewswire
Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM
Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM Majority of patients in this age group with eosinophilic esophagitis receiving Dupixent achieved histologic remission, with improvements sustained up to one yearDupixent is the first-and-only medicine indicated for eosinophilic esophagitis in the US for this age group Paris and Tarrytown, NY, June 26, 2024. The New England Journal of Medicine has published results from a positive pha
